Pfizer’s (PFE) Buy Rating Reaffirmed at Guggenheim

Pfizer (NYSE:PFE)‘s stock had its “buy” rating reissued by investment analysts at Guggenheim in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $33.00 price target on the biopharmaceutical company’s stock. Guggenheim’s price target suggests a potential upside of 29.25% from the stock’s previous close.

Other research analysts have also recently issued research reports about the stock. Bank of America reissued a “neutral” rating and set a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. Wolfe Research initiated coverage on Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Wednesday, October 23rd. Evercore ISI raised Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Finally, Truist Financial dropped their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Stock Performance

Shares of PFE stock opened at $25.53 on Monday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The business has a fifty day moving average of $26.28 and a 200 day moving average of $27.69. The firm has a market capitalization of $144.69 billion, a price-to-earnings ratio of 18.11, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. Pfizer has a 1 year low of $24.48 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the previous year, the company posted $0.10 earnings per share. The company’s revenue was up 24.7% compared to the same quarter last year. As a group, research analysts expect that Pfizer will post 2.95 earnings per share for the current year.

Institutional Investors Weigh In On Pfizer

Institutional investors have recently bought and sold shares of the company. Retirement Wealth Solutions LLC acquired a new stake in shares of Pfizer in the fourth quarter worth approximately $26,000. Rialto Wealth Management LLC purchased a new position in Pfizer in the 4th quarter valued at $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer during the 4th quarter worth $28,000. Gladius Capital Management LP grew its holdings in shares of Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 38,015 shares in the last quarter. Finally, Noble Wealth Management PBC acquired a new stake in shares of Pfizer in the fourth quarter valued at about $31,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.